SCHEMBL2043379

SCHEMBL2043379

O=Cc1c[nH]c(-c2ccco2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.47
KDM4E B2RXH2 6/20 0.47
HPGD P15428 4/20 0.47
GAA P10253 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
POLB P06746 3/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
PKM P14618 2/20 0.41
ALOX15 P16050 2/20 0.41
CASP1 P29466 2/20 0.41
PTPN7 P35236 2/20 0.41
RECQL P46063 2/20 0.41
BLM P54132 2/20 0.41
CASP7 P55210 2/20 0.41
HSD17B10 Q99714 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2456169 0.75 CCR1 (0.37)
SCHEMBL7476978 0.74 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDGAAAPOBEC3G
SCHEMBL27481619 0.74 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDGAAAPOBEC3G
SCHEMBL2041714 0.73 PTK2 (0.34) GAALMNAPKM
SCHEMBL2054265 0.73 NOTUM (0.33) ALDH1A1KDM4ENPC1RAB9A
SCHEMBL15331873 0.72 ALDH1A1 (0.37) ALDH1A1KDM4EHPGDGAAMEN1
SCHEMBL15331207 0.72 ALDH1A1 (0.36) ALDH1A1KDM4EHPGDGAAMEN1
SCHEMBL2559525 0.72
SCHEMBL15331664 0.72 ADORA2A (0.31) ADORA1ADORA2A
SCHEMBL474098 0.72 BTK (0.41) ALDH1A1KDM4EHPGDGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-8927738-B2 2-arylimidazole derivatives as PDE10A enzyme inhibitors H. LUNDBECK A/S (DK) 2015-01-06 US disclosed
US-8927738-B2 2-arylimidazole derivatives as PDE10A enzyme inhibitors H. LUNDBECK A/S (DK) 2015-01-06 US disclosed
EP-2513105-B1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS LUNDBECK & CO AS H (DK) 2014-05-14 EP disclosed
EP-2513105-B1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS LUNDBECK & CO AS H (DK) 2014-05-14 EP disclosed
US-20130289038-A1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2013-10-31 US disclosed
US-20130289038-A1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2013-10-31 US disclosed
US-8501797-B2 (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives H. LUNDBECK A/S (DK) 2013-08-06 US disclosed
US-8501797-B2 (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives H. LUNDBECK A/S (DK) 2013-08-06 US disclosed
US-8501797-B2 (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives H. LUNDBECK A/S (DK) 2013-08-06 US disclosed
US-20120302548-A1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2012-11-29 US disclosed
US-20120302548-A1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2012-11-29 US disclosed
US-20120302548-A1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2012-11-29 US disclosed
EP-2513105-A1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. Lundbeck A/S (DK) 2012-10-24 EP disclosed
WO-2011072696-A1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2011-06-23 WO disclosed
WO-2011072696-A1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289038-A1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS PDE12, PDE3B, PDE5A ALDH1A1 54/4885KDM4E 424/4885HPGD 1059/4885
US-20120302548-A1 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS PDE12, PDE3B, PDE5A ALDH1A1 54/4885KDM4E 424/4885HPGD 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.